Image

Stem Cell Derived Exosomes in the Treatment of Melasma and Its Percutaneous Penetration

Recruiting
18 - 60 years of age
Both
Phase N/A

Powered by AI

Overview

Melasma is a refractory skin disease due to its complex pathogenesis and difficult treatment. Studies have found that human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) could serve as a novel cell-free therapeutic strategy in regenerative and aesthetic medicine. It could potentially treat melasma, but the skin barrier is a challenge. This study aims to explore the safety and efficacy of hUCMSC-Exos in the treatment of melasma and means to promote its percutaneous penetration.

Description

80 patients with melasma treated in our department were divided into four groups. 1565 nm nonablative fractional laser (NAFL) combined with normal saline treatment group was used for Group A. Microneedle,NAFL,a plasma named Peninsula Blue Aurora Shumin Master (PBASM) combined with hUCMSC-Exos were used for the other treatment groups (B, C, and D, respectively). The treatment was given four times with an interval of one month. The degree of pain post-treatment, MASI, improvement rate, physician global assessment score, satisfaction and complications after treatment were evaluated six months later.

Eligibility

Inclusion Criteria:

  • Patients diagnosed with chloasma who meet the clinical diagnostic standards and efficacy standards (revised version) of chloasma and have skin lesions on the face.
        It is hoped that exosomes combined with 1565 non-ablative fractional laser, blue aurora or
        micro-needle can improve facial chloasma.
        Fully understand and understand the content and significance of this study, implementation
        plan, possible benefits, risks and countermeasures, rights and obligations of subjects
        (including privacy protection, free withdrawal), willing to participate in this clinical
        study and able to cooperate well, Those who signed the informed consent form.
        Exclude post-inflammatory pigmentation, malar brown-green nevus, Riehl's melanosis,
        pigmented lichen planus and other skin diseases.
        Subjects who agree not to use other cosmetic treatments related to the study during the
        study period.
        Exclusion Criteria:
          1. Patients who refuse to sign the informed consent form to participate in the trial;
          2. Those with a history of important organ diseases, or a history of autoimmune diseases
             or immune dysfunction;
          3. Abnormal coagulation function, current use of anticoagulants, thrombophilia and
             history of familial genetic diseases;
          4. Pregnant or lactating women;
          5. Patients taking oral contraceptives or hormone replacement therapy during the study
             period or within the past 12 months;
          6. Patients with scar constitution;
          7. Active skin infection;
          8. Those who have a history of multiple severe allergies, a history of hereditary
             allergies, photosensitivity or photosensitivity drugs, such as sulfa drugs and
             tetracyclines, those who are allergic to local anesthetics and those who are allergic
             to lidocaine components, and those who plan to undergo detoxification during the study
             Allergy healer;
          9. History of post-inflammatory pigmentation;
         10. Those who have received treatment for chloasma in the past;
         11. Those who have undergone chemical peeling, dermabrasion or other skin resurfacing on
             their face in the past;
         12. Patients who are participating in other clinical studies;
         13. Other reasons that the researcher considers unsuitable for clinical investigators.

Study details

Melasma

NCT06221787

Fujian Medical University Union Hospital

18 February 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.